Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Zelira Therapeutics Ltd
ZLDZelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter products, including SprinJene, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia. Address: 101 St Georges Terrace, Perth, WA, Australia, 6000
Analytics
Precio Objetivo de WallStreet
17.66 AUDRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave ZLD
Análisis de dividendos ZLD
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout ZLD
Valoración de la acción ZLD
Finanzas ZLD
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |